Rissanen Tuomas T, Uskela Sanna, Siljander Antti, Kärkkäinen Jussi M, Mäntylä Pirjo, Mustonen Juha, Eränen Jaakko
Heart Center, Central Hospital of North Karelia, Joensuu, Finland.
Heart Center, Kuopio University Hospital, Kuopio, Finland.
J Interv Cardiol. 2017 Apr;30(2):139-146. doi: 10.1111/joic.12366. Epub 2017 Jan 23.
We investigated the safety and efficacy of PCI using drug-coated balloon (DCB) after rotational atherectomy (rotablation) in a retrospective single center study in patients with calcified de novo coronary lesions. The majority of patients had an increased risk for bleeding.
DCB has been effective in the treatment of in-stent restenosis, small vessels, and bifurcations. DCB enables short one month dual antiplatelet treatment. No published data exist on the use of DCB after rotablation.
82 PCIs were performed in 65 patients (mean age 72 ± 10 years) using rotablation followed by DCB treatment. The median follow-up time was 17 months. 82% of the patients had at least one risk factor for bleeding such as oral anticoagulation. 32% had an acute coronary syndrome. Median duration of dual antiplatelet treatment was 1 month.
MACE (the composite of cardiovascular death, ischemia-driven target-lesion revascularization [TLR] or non-fatal myocardial infarction) occurred in 14% and 20% of the patients at 12 and 24 months, respectively. The rate of ischemia-driven TLR was 1.5% at 12 months and 3.0% at 24 months. No acute closure of the treated vessel occurred. Bailout stenting was needed in 10% of the PCIs. The incidence of significant bleeding was 9% at 12 months.
This is the first study to show that PCI using DCB after preparation of calcified lesions with rotablation is safe and effective. This novel strategy may be considered especially in patients with a bleeding risk such as those using an oral anticoagulant.
在一项针对初发钙化冠状动脉病变患者的回顾性单中心研究中,我们调查了在旋磨术(rotablation)后使用药物涂层球囊(DCB)进行经皮冠状动脉介入治疗(PCI)的安全性和有效性。大多数患者出血风险增加。
DCB已有效地用于治疗支架内再狭窄、小血管病变和分叉病变。DCB可实现为期一个月的短期双联抗血小板治疗。目前尚无关于旋磨术后使用DCB的公开数据。
对65例患者(平均年龄72±10岁)进行了82次PCI,先进行旋磨术,然后进行DCB治疗。中位随访时间为17个月。82%的患者至少有一项出血风险因素,如口服抗凝药。32%的患者患有急性冠状动脉综合征。双联抗血小板治疗的中位持续时间为1个月。
主要不良心血管事件(MACE,即心血管死亡、缺血驱动的靶病变血管重建术[TLR]或非致命性心肌梗死的复合事件)在12个月和24个月时分别发生在14%和20%的患者中。缺血驱动的TLR发生率在12个月时为1.5%,在24个月时为3.0%。治疗血管未发生急性闭塞。10%的PCI需要补救性置入支架。12个月时严重出血的发生率为9%。
这是第一项表明在使用旋磨术预处理钙化病变后使用DCB进行PCI是安全有效的研究。这种新策略尤其适用于有出血风险的患者,如正在使用口服抗凝药的患者。